Idiopathic Inflammatory Myopathy Clinical Trials

4 recruiting

Idiopathic Inflammatory Myopathy Trials at a Glance

10 actively recruiting trials for idiopathic inflammatory myopathy are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Aurora, Chicago, and Jacksonville. Lead sponsors running idiopathic inflammatory myopathy studies include Beijing GoBroad Hospital, Cabaletta Bio, and Allogene Therapeutics.

Browse idiopathic inflammatory myopathy trials by phase

Treatments under study

About Idiopathic Inflammatory Myopathy Clinical Trials

Looking for clinical trials for Idiopathic Inflammatory Myopathy? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic Inflammatory Myopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic Inflammatory Myopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory Myopathy
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Phase 1

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Systemic SclerosisIdiopathic Inflammatory MyopathySystemic Lupus Erythematosus (With and Without Nephritis)
Allogene Therapeutics66 enrolled13 locationsNCT07085104
Recruiting
Phase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955
Recruiting
Early Phase 1

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy (IIM)
Daishi Tian12 enrolled1 locationNCT07086404
Recruiting
Early Phase 1

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

Recurrent or Refractory Systemic Lupus ErythematosusRecurrent or Refractory IgG4 Related DiseasesRecurrent or Refractory Systemic Sclerosis+2 more
Tongji Hospital45 enrolled1 locationNCT07339540
Recruiting
Not Applicable

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Systemic Lupus ErythematosusSjogren's SyndromeSystemic Sclerosis (SSc)+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University15 enrolled1 locationNCT06614270
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+10 more
University of Bonn120 enrolled1 locationNCT07150000
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)+1 more
Polina Stepensky60 enrolled1 locationNCT07085676
Recruiting
Phase 1

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)+1 more
Beijing GoBroad Hospital44 enrolled2 locationsNCT06980597